AstraZeneca spearheads lung cancer alliance aiming to boost survival rates - FiercePharma

AstraZeneca spearheads lung cancer alliance aiming to boost survival rates  FiercePharma

AstraZeneca wants to double the five-year lung cancer survival rate by 2025. That's an ambitious target for a disease that's the leading cause of cancer deaths in ...



Comments

Popular posts from this blog

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...

Oncology: The disease, dynamics & challenges of market research

Division of Continuing Professional Development